Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline – ml-eu.globenewswire.com

Your email address will not be published. Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Δ